Insights from 2024 EHA Annual Meeting
Videos
2024 ASCO® Annual Meeting Insights Hub
Highlights of Recent Updates in CML: Impact on Practice
FEATURING
Ehab Atallah
- 53 views
- August 27, 2024
International CML Foundation
Biological Highlights in CML From EHA
FEATURING
Nick Cross
- 49 views
- August 9, 2024
International CML Foundation
Clinical Highlights in CML From EHA
FEATURING
Andreas Hochhaus
- 45 views
- August 9, 2024
Insights from 2024 EHA Annual Meeting
Top 5 Impactful MPN Abstracts From Summer Conferences
FEATURING
Prithviraj Bose
- 159 views
- July 31, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagraxofusp
FEATURING
Emanuele Angelucci
- 228 views
- July 23, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Limited Stage HL - Current SOC, Future Directions, and Incorporating BV and Nivo
FEATURING
Steven Park
- 60 views
- July 18, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Sonrotoclax and Zanubrutinib Combination Therapy for R/R MCL
FEATURING
Constantine Tam
- 25 views
- July 18, 2024
Insights from 2024 EHA Annual Meeting
AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024
FEATURING
Talha Badar
- 765 views
- July 16, 2024
- 4
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's Lymphoma With AVD+BV+Nivo
FEATURING
Maher Salamoon
- 165 views
- July 9, 2024
- 5
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL
FEATURING
Stephen S. Opat
- 55 views
- July 3, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Factor AML
FEATURING
Gautam Borthakur
- 150 views
- July 1, 2024
- 2
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: PROs After Epcoritamab in R/R Follicular Lymphoma
FEATURING
Wojciech Jurczak
- 34 views
- July 1, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Axicabtagene Ciloleucel in R/R Primary Mediastinal B-Cell Lymphoma
FEATURING
Jean Galtier
- 19 views
- June 30, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: SYMPATICO Study - Ibrutinib + Venetoclax in MCL With TP53 Mutations
FEATURING
Wojciech Jurczak
- 40 views
- June 30, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: CD20-Targeted CAR-T Therapy for BTKi-Refractory WM/LPL
FEATURING
Mazyar Shadman
- 66 views
- June 28, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in High-Risk CLL
FEATURING
Catherine Coombs
- 88 views
- June 28, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated IDH1 AML
FEATURING
Jorge Cortés
- 27 views
- June 28, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Daratumumab for iTTP
FEATURING
Júlia Weisinger
- 138 views
- June 28, 2024
Insights from 2024 EHA Annual Meeting
Highlights in Plasma Cell Disorders From ASCO® and EHA
FEATURING
Samer Al Hadidi
- 481 views
- June 27, 2024
- 7
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors
FEATURING
Joshua Zeidner
- 69 views
- June 26, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R AML
FEATURING
Wei-Ying Jen
- 250 views
- June 26, 2024
- 2
Insights from 2024 EHA Annual Meeting
Responder Analysis From the PhALLCON Trial: Ponatinib vs. Imatinib in Newly Diagnosed Ph+ ALL
FEATURING
Jose-Maria Ribera
- 107 views
- June 24, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and EHA
FEATURING
Kerry Rogers,
Jennifer Woyach
- 320 views
- June 21, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transplant-Eligible NDMM
FEATURING
Pieter Sonneveld
- 98 views
- June 20, 2024